FLJ35220 Inhibitors
The chemical class of FLJ35220 Inhibitors includes various compounds that can potentially inhibit the activity of the FLJ35220 protein by targeting signaling pathways in which it is involved. FLJ35220 is likely associated with pathways such as phosphoinositide 3-kinase (PI3K), mechanistic target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), and Janus kinase (JAK) signaling.
Direct inhibitors such as wortmannin, LY294002, rapamycin, U0126, SB203580, PD98059, LY3214996, AZD6244, SB202190, ruxolitinib, MK-2206, and trametinib target key components or regulators of these pathways, potentially disrupting FLJ35220-mediated cellular functions. By inhibiting the activity of these signaling molecules, these compounds can interfere with downstream signaling cascades involving FLJ35220, thereby modulating its function indirectly. Understanding the interplay between FLJ35220 and these signaling pathways is crucial for elucidating its physiological roles and may provide insights into strategies for diseases associated with dysregulated FLJ35220 signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3Ks) by covalently binding to their catalytic subunit. FLJ35220 may be involved in PI3K signaling pathways, and inhibition of PI3Ks by wortmannin can disrupt its downstream effects. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinases (PI3Ks), targeting their catalytic subunit. By blocking PI3K activity, LY294002 can interfere with signaling pathways involving FLJ35220, potentially inhibiting its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mechanistic target of rapamycin (mTOR), a key regulator of cell growth and proliferation. FLJ35220 may be involved in mTOR signaling pathways, and inhibition of mTOR by rapamycin can affect its downstream effects. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which lies upstream of extracellular signal-regulated kinase (ERK). Inhibition of MEK by U0126 can disrupt signaling pathways involving FLJ35220. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), a key regulator of cellular responses to stress and inflammation. Inhibition of p38 MAPK by SB203580 can influence pathways involving FLJ35220. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, targeting its activation loop. By blocking MEK activity, PD98059 can interfere with downstream signaling pathways involving FLJ35220, particularly those mediated by the ERK pathway. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 is a selective inhibitor of ERK1/2, downstream effectors of the MAPK signaling pathway. Inhibition of ERK1/2 by LY3214996 can disrupt signaling cascades involving FLJ35220, potentially inhibiting its function. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
SB202190 is a selective inhibitor of p38 MAPK, which plays a role in stress response and inflammation. Inhibition of p38 MAPK by SB202190 can disrupt pathways involving FLJ35220, potentially inhibiting its cellular functions. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a selective inhibitor of Janus kinases (JAKs), which are involved in cytokine signaling pathways. FLJ35220 may interact with JAK-mediated pathways, and inhibition of JAKs by ruxolitinib can affect its downstream effects. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is a selective inhibitor of AKT, a key component of the PI3K signaling pathway. Inhibition of AKT by MK-2206 can disrupt downstream signaling pathways involving FLJ35220, potentially inhibiting its cellular functions. | ||||||